Aspirin "failures," clopidogrel added to aspirin, and secondary stroke prevention in veterans presenting with TIA or mild-to-moderate ischemic stroke.
Our objective was to investigate whether clopidogrel added to low-dose aspirin reduced vascular events in male patients at our VA hospital who had "failed" aspirin therapy because of a mild-to-moderate stroke or a transient ischemic attack. Of 179 consecutive patients who both reported daily aspirin usage at the time of their newest ischemic event as well as were then operationally defined as aspirin "failures," 134 (group A) were treated with combined aspirin-clopidogrel, 15 (group B) underwent an early arterial procedure, 25 (group C) were anticoagulated, and 5 were not entered or continued because of either non-compliance or a refusal to participate. Study therapies were modified because of a vascular event in 4.5% of group A (one non-fatal ischemic stroke, one non-fatal myocardial infarction, and four transient ischemic attacks) and 33% of group B (one non-fatal ischemic stroke, one non-fatal myocardial infarction, and three transient ischemic attacks). No major or fatal bleeding events occurred in any of those on combined aspirin-clopidogrel therapy, with minor bleeding in 10 of 134 (7.5%) and 2 of 15 (13.3%) of group A and B patients, respectively. Patients were followed for 18 +/- 9.7 months. Combined aspirin-clopidogrel therapy appears both safe as well as effective in this single-center, observational study.
Levine
Ross L
RL
Department of Neurology, William S. Middleton Memorial Veterans Affairs Medical Center, Madison, Wisconsin, USA.
Dixit
Shankar N
SN
Dulli
Douglas A
DA
Khasru
Muhammed A
MA